Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006

Psychiatric Services

Volumn 59, Issue 5, 2008, Pages 567-569

  Sernyak, Michael J ^a,b   Rosenheck, Robert A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE;

ARTICLE; DRUG MARKETING; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT CARE; PRESCRIPTION; SCHIZOPHRENIA; VETERAN;

EID: 46849090041     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2008.59.5.567     Document Type: Article

References (15)

1. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-1223, 2005
2. Rosenheck R, Perlick D, Bingham S, et al: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290:2693-2702, 2003
3. Valenstein M, McCarthy J, Ignacio R, et al: Patient- and facility-level factors associated with diffusion of a new antipsychotic in the VA health system. Psychiatric Services 57:70-76, 2006
4. Rothbard AB, Kuno E, Foley K: Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophrenia Bulletin 29:531-540, 2003
5. Leslie D, Rosenheck R: Seventh Annual Report on Pharmacotherapy of Schizophrenia in the Department of Veterans Affairs. West Haven, Conn, Northeast Program Evaluation Center, 2006
6. Chen RS, Nadkarni PM, Levin FL, et al: Using a computer database to monitor compliance with pharmacotherapeutic guidelines for schizophrenia. Psychiatric Services 51:791-794, 2000
7. Ziprasidone Criteria for Use. Washington, DC, Department of Veterans Affairs Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel, Apr 2002. Available at www.pbm.va.gov/criteria/zipracriteria.pdf
8. Wirshing DA, Spellberg BJ, Erhart SM, et al: Novel antipsychotics and new onset diabetes. Biological Psychiatry 44:778-783, 1998
9. Koller EA, Doraiswamy PM: Olanzapine-associated diabetes mellitus. Pharmacotherapy 22:841-852, 2002
10. Sernyak MJ, Leslie DL, Alarcon RD, et al: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. American Journal of Psychiatry 159:561-566, 2002
11. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601, 2004
12. Berenson A: Eli Lilly said to play down risk of top pill. New York Times, Dec 17, 2006. Available at www.nytimes.com/2006/12/17/business/17drug.html
13. Allison DB, Mentore JL, Heo M, et al: Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156:1686-1696, 1999
14. Recommendations for Atypical Antipsychotic Use in Schizophrenia and Schizoaffective Disorders. Washington, DC, Department of Veterans Affairs Pharmacy Benefits Management Strategic Healthcare Group Medical Advisory Panel and Mental Health Strategic Healthcare Group, Mar 30, 2007. Available at www.pbm.va.gov. Accessed on June 29, 2007
15. Cascade E, Kalali A: Use of antipsychotics pre- and post-dissemination of CATIE data. Psychiatry 4(5):21-23, 2007